[ 18 F]BIBD-239: A First-in-Human PET Radiotracer with Dual Diagnostic Utility for Glioma Grading and Myocardial Imaging
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Xin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China. Hauptthemen laut MEDLINE: Glioma, Positron-Emission Tomography, Radiopharmaceuticals, Fluorine Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Capital Medical University, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
To verify its application potential in the field of cardiac and cerebral disease diagnosis, the first human experiment of [18F]BIBD-239 was reported. Synthesized via a GMP-compliant automated process on a CFN-MPS200 synthesizer (per Chinese Pharmacopoeia 2020), it achieved radiochemical purity >95%, nondecay-corrected yield >15%, and molar activity >120 GBq/μmol (total synthesis time 80 ± 5 min) under optimized conditions (95 °C, 10 min). Preclinical studies in rats confirmed TSPO-specific binding. First-in-human studies (6 healthy volunteers, 1 high-grade glioma (HGG), 1 low-grade glioma (LGG)) showed it rapidly crossed the blood-brain barrier with low normal brain retention and high sustained myocardial uptake without in vivo defluorination. HGG had higher tumor-to-background ratios (3.09) than LGG (2.33), with uptake beyond MRI-enhanced regions, correlating with histopathology. The whole-body effective dose (0.0145 ± 0.0018 mSv/MBq) was lower than [18F]FDG. [18F]BIBD-239 has robust synthesis, favorable pharmacokinetics, and TSPO-specific binding, enabling dual utility in noninvasive glioma grading and glucose-independent myocardial imaging, supporting translation in neuro-oncology and cardiovascular assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China.
- Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.
- School of Pharmaceutical Science, Capital Medical University, Beijing 100069, China.
ORCID-Profile: Zehui Wu
Förderung
- Capital Medical University
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Li, X., Zheng, W., Zhang, Y., Cheng, X., Liu, Y., Zhang, L., Chen, H., Ai, L., & Wu, Z. (2025). [ 18 F]BIBD-239: A First-in-Human PET Radiotracer with Dual Diagnostic Utility for Glioma Grading and Myocardial Imaging. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01088
Vancouver
Wang X, Li X, Zheng W, Zhang Y, Cheng X, Liu Y, et al. [ 18 F]BIBD-239: A First-in-Human PET Radiotracer with Dual Diagnostic Utility for Glioma Grading and Myocardial Imaging. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01088
BibTeX
@article{Wang2025,
author = {Wang, Xin and Li, Xiaotong and Zheng, Wei and Zhang, Yongzhong and Cheng, Xuebo and Liu, Yajing and Zhang, Lu and Chen, Hualong and Ai, Lin and Wu, Zehui},
title = {[ 18 F]BIBD-239: A First-in-Human PET Radiotracer with Dual Diagnostic Utility for Glioma Grading and Myocardial Imaging},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01088}
}
EUVIMED